Dose regimen adjustment for milrinone in congestive heart failure patients with moderate and severe renal failure
- PMID: 8583366
- DOI: 10.1111/j.2042-7158.1995.tb05853.x
Dose regimen adjustment for milrinone in congestive heart failure patients with moderate and severe renal failure
Abstract
This study was designed to test a proposed dose modification for intravenous milrinone in congestive heart failure patients (CHF, NYHA I-II) with either moderate or severe renal impairment. All the patients were administered an intravenous loading dose of drug at 50 micrograms kg-1 over 10 min. This was followed by an 18 h maintenance infusion of milrinone at 0.45 or 0.35 micrograms kg-1 min-1 for the moderate (chromium-EDTA clearance of 31-75 mL min-1, n = 10) and severe renally impaired subjects (chromium-EDTA of clearance 10-30 mL min-1, n = 11), respectively. Plasma and urine samples were collected for up to 34 h and analysed for parent drug by validated HPLC methods. The mean (+/- s.d.) steady-state plasma concentrations of milrinone were within the therapeutic range (100-300 ng mL-1) for both groups, with values of 239 +/- 71 ng mL-1 and 269 +/- 32 ng mL-1 for the moderate and severe patients, respectively. No statistical differences were observed between the steady-state values for the two groups. With the exception of two patients per group, individual steady-state levels were also within the therapeutic range. Those outside the nominal range showed steady-state levels, ranging between 308 and 353 ng mL-1, that were not associated with any serious adverse events.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Pharmacokinetics and pharmacodynamics of milrinone lactate in pediatric patients with septic shock.J Pediatr. 1998 Feb;132(2):329-34. doi: 10.1016/s0022-3476(98)70454-8. J Pediatr. 1998. PMID: 9506650 Clinical Trial.
-
Pharmacokinetics of intravenous milrinone in patients undergoing cardiac surgery.Anesthesiology. 1994 Sep;81(3):616-22. doi: 10.1097/00000542-199409000-00014. Anesthesiology. 1994. PMID: 8092507
-
Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass.J Cardiothorac Vasc Anesth. 1995 Jun;9(3):264-71. doi: 10.1016/s1053-0770(05)80319-2. J Cardiothorac Vasc Anesth. 1995. PMID: 7669958 Clinical Trial.
-
Milrinone. A preliminary review of its pharmacological properties and therapeutic use.Drugs. 1988 Aug;36(2):158-92. doi: 10.2165/00003495-198836020-00003. Drugs. 1988. PMID: 3053125 Review.
-
Role of milrinone in the management of congestive heart failure.DICP. 1989 May;23(5):357-62. doi: 10.1177/106002808902300501. DICP. 1989. PMID: 2658377 Review.
Cited by
-
Time-Varying Clearance in Milrinone Pharmacokinetics from Premature Neonates to Adolescents.Clin Pharmacokinet. 2024 May;63(5):695-706. doi: 10.1007/s40262-024-01372-5. Epub 2024 Apr 13. Clin Pharmacokinet. 2024. PMID: 38613610 Free PMC article.
-
A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients.Can J Anaesth. 2016 Oct;63(10):1140-1153. doi: 10.1007/s12630-016-0709-8. Epub 2016 Jul 28. Can J Anaesth. 2016. PMID: 27470232 Clinical Trial. English.
-
Evaluation and optimisation of current milrinone prescribing for the treatment and prevention of low cardiac output syndrome in paediatric patients after open heart surgery using a physiology-based pharmacokinetic drug-disease model.Clin Pharmacokinet. 2014 Jan;53(1):51-72. doi: 10.1007/s40262-013-0096-z. Clin Pharmacokinet. 2014. PMID: 23839530
-
Use of milrinone in critically ill children.Can J Hosp Pharm. 2010 Nov;63(6):420-8. doi: 10.4212/cjhp.v63i6.960. Can J Hosp Pharm. 2010. PMID: 22479014 Free PMC article.
-
Pharmacokinetics and pharmacodynamics of intravenous inotropic agents.Clin Pharmacokinet. 2004;43(3):187-203. doi: 10.2165/00003088-200443030-00003. Clin Pharmacokinet. 2004. PMID: 14871156 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous